Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

OM-85 i pediatriske residiverende luftveisinfeksjoner med tungpustethet i nedre luftveier

24. september 2026 oppdatert av: OM Pharma SA

En randomisert, placebokontrollert, 3-arms, dobbeltblind, multisenter, fase 4-studie for å vurdere effekten av OM-85 (Broncho-Vaxom) kort- og langtidsbehandling kontra placebo i forebygging av luftveisinfeksjoner hos barn i alderen mellom 6 måneder og 5 år med tungpustethet i nedre luftveier

This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children aged between 6 months and 5 years.

Studieoversikt

Detaljert beskrivelse

This is a Phase 4, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of short- and long-term treatment with OM-85.

The study will consist of screening (up to 20 days before randomisation), Treatment period of 12 months, and an Observational period of 6 months.

The subjects will be randomised in a ratio of 1:1:1 ratio to receive either OM-85 for 12 consecutive months (BV-12 arm), or OM-85 for 3 consecutive months followed by matching placebo for 9 consecutive months (BV-3 arm), or placebo for 12 consecutive months (Placebo arm).

The expected duration of subject participation is 18 months (+20 days).

Studietype

Intervensjonell

Registrering (Faktiske)

525

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Bari, Italia, 70126
        • Osp.Pediatr.Giov.XXIII,AOUC P.Bari
      • Bergamo, Italia, 24127
        • ASST Papa GiovanniXXIII,Mat.Inf.Ped
    • Parma
      • Parma, Parma, Italia, 43100
        • Azienda ospedalo universitaria
    • Pavia
      • Pavia, Pavia, Italia, 27100
        • Universita degli Studi di Pavia - Fondazione IRCCS Policlini
    • Pisa
      • Pisa, Pisa, Italia, 56126
        • SO S.Chiara, AOU Pisana
      • Krakow, Polen, 31-411
        • Centrum Medyczne PROMED
      • Rzeszów, Polen, 35-612
        • Podkarpacki Osrodek Pulmonologii i Alergologii Sp. z o.o.
      • Skierniewice, Polen, 96-100
        • Velocity Skierniewice Sp. z o.o.
      • Warsaw, Polen, 01-231
        • Przychodnia Specjalistyczna Prosen-Med NZOZ
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 31-624
        • Malopolskie Centrum Alergologii
      • Tarnów, Lesser Poland Voivodeship, Polen, 33-100
        • ALERGO-MED Specjalistyczna Przychodnia Lekarska Spolka z o.o.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-552
        • Centrum Alergologii Specjalistyczna Przychodnia Alergologiczna
    • Lódzkie
      • Lodz, Lódzkie, Polen, 90-329
        • WWCOiT im. M. Kopernika w Lodzi, Osrodek Pediatryczny im. dr J.Korczaka
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polen, 15-879
        • NZOZ E-Vita
    • Silesian Voivodeship
      • Częstochowa, Silesian Voivodeship, Polen, 42-217
        • Centrum Medyczne Pratia Czestochowa
      • Siemianowice Śląskie, Silesian Voivodeship, Polen, 41-103
        • NZLA Michalkowice - Jarosz i Partnerzy Spolka Lekarska
    • Świętokrzyskie Voivodeship
      • Skarżysko-Kamienna, Świętokrzyskie Voivodeship, Polen, 26-110
        • NSZOZ Puls - Med Anna Bogusz, Agnieszka Musielak Sp.J.
      • Edinburgh, Storbritannia, EH9 1LF
        • Royal Hospital for Children and Young People
      • London, Storbritannia, SE5 9RS
        • King's College Hospital
      • London, Storbritannia, E1 4NS
        • Royal London Hospital
    • East Sussex
      • Brighton, East Sussex, Storbritannia, BN2 5BE
        • Brighton And Sussex University Hospitals NHS Trust
    • Manchester
      • Manchester, Manchester, Storbritannia, M13 9WL
        • Royal Manchester Children's Hospital - Paediatrics - Paediatrics
    • Nottingham
      • Nottingham, Nottingham, Storbritannia, NG7 2UH
        • Nottingham University Hospitals NHS Trust - Queen's Medical Centre
      • Geneva, Sveits, 1205
        • Hôpitaux Universitaires de Genève (HUG)
      • Zurich, Sveits, 8032
        • Universitaets-Kinderklinik - Kinderspital Zuerich
    • Canton of Bern
      • Bern, Canton of Bern, Sveits, 3010
        • Inselspital Bern Kinderklinik
    • Canton of Vaud
      • Lausanne, Canton of Vaud, Sveits, 1011
        • CHUV-Centre Hopitalier Universitaire Vaudois
    • Bavaria
      • München, Bavaria, Tyskland, 80337
        • Ludwig Maximilians Universität München
      • Schönau am Königssee, Bavaria, Tyskland, 83471
        • Clinical Research & Healthcare GmbH
    • Lower Saxony
      • Hanover, Lower Saxony, Tyskland, 30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Bochum, North Rhine-Westphalia, Tyskland, 44791
        • St. Josef-Hospital
      • Cologne, North Rhine-Westphalia, Tyskland, 50937
        • University Hospital Cologne AöR
      • Düsseldorf, North Rhine-Westphalia, Tyskland, 40217
        • Ev. Krankenhaus Düsseldorf
      • Mönchengladbach, North Rhine-Westphalia, Tyskland, 41236
        • Praxis Köllges
      • Wesel, North Rhine-Westphalia, Tyskland, 46483
        • Marien-Hospital Wesel gGmbH
    • Schleswig-Holstein
      • Lübeck, Schleswig-Holstein, Tyskland, 23538
        • Universitätsklinikum Schleswig-Holstein Campus Lübeck
      • Balassagyarmat, Ungarn, H-2660
        • Dr. Kenessey Albert Korhaz-Rendelointezet
      • Budapest, Ungarn, 1089
        • Heim Pal Orszagos Gyermekgyogyaszati Intezet
      • Budapest, Ungarn, 1083
        • Semmelweis Egyetem I.sz. Gyermekgyogyaszati Klinika
      • Gyula, Ungarn, 5700
        • Sanitas Diagnosztikai és Rehabilitációs Központ
      • Miskolc, Ungarn, 3527
        • Futurenest Kft.
    • Csongrád megye
      • Szeged, Csongrád megye, Ungarn, 6720
        • Aranyklinika Kft

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 måneder til 5 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Children of either gender aged between 6 months and 5 years, at Baseline/Randomisation (Visit 2) inclusive.
  • For children ≥1 year of age, ≥4 RTIs (as reported by parents or LAR of subject), including ≥2 episodes of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 12 months prior to enrolment.

OR

  • For children <1 year of age, ≥2 RTIs (as reported by parents or LAR of subject), including ≥1 episode of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 6 months prior to enrolment.
  • Parents or LAR of subject have provided the appropriate written informed consent. Written informed consent must be provided before any study-specific procedures are performed including screening procedures.

Exclusion Criteria:

  • Anatomic alterations of the respiratory tract.

  • Other chronic respiratory diseases (e.g., tuberculosis, cystic fibrosis).

  • Any autoimmune disease.

  • HIV infection or any type of congenital or iatrogenic immune deficiency (including IgA deficiency).

  • Known severe congenital heart disease.

  • Haematologic diseases.

  • Liver or kidney failure.

  • New-borns before 34 weeks of gestational age.

  • Malnutrition as per World Health Organization (WHO) definition.

  • Any known neoplasia or malignancy.

  • Treatment with the following medications:

    1. Injection or oral administration of steroids within 4 weeks prior to study enrolment.
    2. Previous and/or concomitant immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to study enrolment.
  • Previous use within last 6 months of enrolment or ongoing use of bacterial lysates.

  • Any major surgery within the last 3 months prior to study enrolment.

  • Known allergy or previous intolerance to investigational medicinal products (IMP).

  • Any other clinical conditions, that in the opinion of the Investigator, would not allow safe completion of the clinical study.

  • Other household members have previously been randomised in this clinical study.

  • Subjects' families expected to relocate out of study area within 24 months of the initiation of the study.

  • Currently enrolled in or has completed any other investigational device or drug study or receiving other investigational agent(s) within <30 days prior to screening.

  • Parents or legally acceptable representative (LAR) who do not have access to internet connection.

  • Wheezing documented to be caused by gastroesophageal reflux.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: BV-12

Subjects will receive OM-85 treatment for 12 consecutive months. (10 days per month)

Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)

Eksperimentell: BV-3

Subjects will receive OM-85 treatment for 3 consecutive months, followed by matching placebo for 9 consecutive months. (10 days per month)

Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)

Placebo komparator: Placebo

Subjects will receive matching placebo for 12 consecutive months. (10 days per month)

Subjects will be administered Placebo once daily. (10 days per month)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of respiratory tract infections (RTIs)
Tidsramme: 12 Months

The number of RTIs experienced by a subject during the Treatment period will be assessed.

12 Months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of wheezing lower respiratory infections (wLRIs) experienced by a subject
Tidsramme: 12 Months

The number of wLRIs experienced by a subject during the Treatment period will be assessed. This is the key secondary endpoint

12 Months
Rate of wLRIs
Tidsramme: 18 Months

The number of wLRIs experienced by a subject during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Rate of respiratory tract infections (RTIs)
Tidsramme: 18 Months

The number of RTIs experienced by a subject during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Proportion of subjects with recurrent RTIs
Tidsramme: 18 Months

The proportion of subjects experiencing ≥3 RTIs during the first 6 months of Treatment period, the proportion of subjects experiencing ≥4 RTIs during the full 12-month Treatment period and the proportion of subjects experiencing ≥6 RTIs during the full 12-month Treatment period and during the whole study period will be assessed.

18 Months
Proportion of subjects with wLRIs
Tidsramme: 18 Months

The proportion of subjects with wLRIs during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Rate of severe wheezing lower respiratory illness (SwLRIs)
Tidsramme: 18 Months

The number of SwLRIs experienced by a subject during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Proportion of subjects with SwLRIs
Tidsramme: 18 Months

The proportion of subjects with SwLRIs during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Time to first, second and third RTI and wLRI
Tidsramme: 18 Months

Time to first, second and third RTI and wLRI during the whole study period will be assessed.

18 Months
Mean duration in days per RTI and acute RTI
Tidsramme: 18 Months

Mean duration in days per RTI and mean duration in days per acute RTI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Mean duration in days per wLRI
Tidsramme: 18 Months

Mean duration in days per wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Mean duration in days per SwLRI
Tidsramme: 18 months

Mean duration in days per SwLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 months
Number of healthcare resource utilisations
Tidsramme: 18 Months

Number of healthcare resource utilisations (inpatient hospitalisations, visits to emergency rooms, or to a physician/health care provider) due to an RTI and/or a wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Number of absent days from daycare
Tidsramme: 18 Months

Number of absent days from daycare due to an RTI and/or a wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Number of antibiotic treatments for a respiratory event
Tidsramme: 18 Months

Number of antibiotic treatments for a respiratory event during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Duration of antibiotic treatments for a respiratory event
Tidsramme: 18 Months

Duration of antibiotic treatments for a respiratory event during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Number of systemic corticosteroids, inhaled corticosteroids (ICS) and β2-agonist treatments for a wLRI
Tidsramme: 18 Months

Number of systemic corticosteroids, ICS and β2-agonist treatments for a wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Duration of systemic corticosteroids, ICS and β2-agonist treatments for a wLRI
Tidsramme: 18 Months

Duration of systemic corticosteroids, ICS and β2-agonist treatments for a wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Symptom duration as per the adapted Wisconsin Upper Respiratory Symptom Survey for Kids (WURSS-K) questionnaire
Tidsramme: 18 Months

Symptom duration during the Treatment period, during the Observational period, and during the whole study period will be assessed using WURSS-K questionnaire. Adapted WURSS-K is a valid and reliable illness-specific quality of life instrument that evaluates the impacts of RTIs on children.

18 Months
Symptom types as per the adapted WURSS-K questionnaire
Tidsramme: 18 Months

Symptom types during the Treatment period, during the Observational period, and during the whole study period will be assessed using WURSS-K questionnaire. Adapted WURSS is a valid and reliable illness-specific quality of life instrument that evaluates the impacts of RTIs on children.

18 Months
Symptom severity as per the adapted WURSS-K questionnaire
Tidsramme: 18 Months

Symptom severity during the Treatment period, during the Observational period, and during the whole study period will be assessed using WURSS-K questionnaire. Adapted WURSS is a valid and reliable illness-specific quality of life instrument that evaluates the impacts of RTIs on children.

18 Months
Proportion of subjects who have not used antibiotics as rescue medication for RTI
Tidsramme: 18 Months

The proportion of subjects who have not used antibiotics as rescue medication for RTI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Proportion of subjects who have not been hospitalised for an RTI
Tidsramme: 18 Months

The proportion of subjects who have not been hospitalised for an RTI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Proportion of subjects who have not been administered a systemic corticosteroid for wLRI
Tidsramme: 18 Months

The proportion of subjects who have not been administered a systemic corticosteroid for wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months
Proportion of subjects who have not been hospitalised for more than 1 day for wLRI
Tidsramme: 18 Months

The proportion of subjects who have not been hospitalised for more than 1 day for wLRI during the Treatment period, during the Observational period, and during the whole study period will be assessed.

18 Months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of subjects with adverse events and serious adverse event
Tidsramme: 18 Months

The safety of short- and long-term treatment with OM-85 vs. placebo in children aged between 6 months and 5 years with recurrent RTIs associated with wLRI during the Treatment period and during the Observational period will be assessed.

18 Months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. desember 2022

Primær fullføring (Faktiske)

10. mars 2026

Studiet fullført (Faktiske)

16. september 2026

Datoer for studieregistrering

Først innsendt

14. desember 2022

Først innsendt som oppfylte QC-kriteriene

22. desember 2022

Først lagt ut (Faktiske)

10. januar 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • BV-2020/08
  • 2024-511581-37-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere